Valuation: Candel Therapeutics, Inc.

Market Cap 722M 632M 582M 539M 1.02B 68.5B 1.04B 6.98B 2.71B 33.8B 2.71B 2.65B 117B P/E 2026 *
-11x
P/E 2027 * -17.3x
Enterprise Value 722M 632M 582M 539M 1.02B 68.5B 1.04B 6.98B 2.71B 33.8B 2.71B 2.65B 117B EV / Sales 2026 *
-
EV / Sales 2027 * 13.7x
Free-Float
84.33%
Yield 2026 *
-
Yield 2027 * -
06-30 Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug DJ
06-30 Candel Therapeutics, Inc. Initiates Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec In Advanced Non-Small Cell Lung Cancer Patients With Inadequate Response To Immune Checkpoint Inhibitors CI
06-25 Candel Therapeutics, Inc. Appoints Mark Sims as Chief Commercial Officer, Effective July 6, 2026 CI
06-21 Candel Therapeutics, Inc.(NasdaqGM:CADL) added to S&P Biotechnology Select Industry Index CI
06-02 Candel Therapeutics, Inc. Announces Publication in the Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (Can-2409) in Localized Prostate Cancer CI
05-20 Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-20 Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-20 54,895,849 Common Stock of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-15 Candel Therapeutics reports extended clinical benefit over multiple clinical endpoints in patients from phase 3 trial of aglatimagene besadenovec (CAN-2409) RE
05-15 Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (CAN-2409) In Localized Prostate Cancer Under Prolonged Follow-Up At AUA 2026 Annual Meeting CI
05-15 Candel Therapeutics, Inc. - Special Call
05-14 Candel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-29 Candel Therapeutics Enters Commercialization Agreement with EVERSANA for Potential U.S. Launch of Aglatimagene Besadenovec CI

Last Transcript: Candel Therapeutics, Inc.

1 day-2.44%
1 week-2.73%
Current month-6.70%
1 month+13.06%
3 months+94.14%
6 months+73.15%
Current year+70.09%
1 week 9.57
Extreme 9.57
10.45
1 month 7.93
Extreme 7.93
11.36
Current year 4.44
Extreme 4.44
11.36
1 year 4.35
Extreme 4.35
11.36
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.78
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 2020-08-31
Director of Finance/CFO 41 2024-01-11
Chief Tech/Sci/R&D Officer 57 2022-09-11
Director TitleAgeSince
Director/Board Member 80 2017-08-31
Director/Board Member 66 2020-08-31
Chairman 70 2021-07-14
Date Insider Type Main position Quantity % Market Cap.
06-29Free

Director

381 0.0005%
06-29Free

Director

1,331 0.0018%
06-29Free

Chairman

2,199 0.0030%
Change 5-day change 1-year change 3-year change Capi.($)
-2.49%-2.73%+83.40%+700.83% 722M
+0.17%+5.35%+3.05%+9.52% 49.74B
+0.50%+3.00%+430.02%+609.81% 40.49B
-1.31%+5.10%+24.99%+58.71% 34.35B
-2.76%+0.51%+24.18%-6.92% 34.75B
+1.31%-0.56%+5.12%+33.90% 26.98B
+1.84%+1.63% - - 16.58B
-4.03%-2.91%+63.64%+118.27% 15.6B
-1.12%+8.24%+107.35%+105.16% 14.27B
-2.52%-1.87%+12.57%+17.98% 13.76B
Average -1.06%+3.35%+83.81%+183.03% 24.73B
Weighted average by Cap. -0.64%+4.56%+96.06%+138.53%

Financials

2026 *2027 *
Net sales - 52.65M 46.07M 42.46M 39.36M 74.71M 5B 75.92M 509M 198M 2.47B 198M 193M 8.52B
Net income -60.22M -52.7M -48.57M -45.02M -85.46M -5.72B -86.83M -582M -226M -2.82B -226M -221M -9.75B -42.95M -37.59M -34.64M -32.11M -60.95M -4.08B -61.93M -415M -162M -2.01B -161M -158M -6.95B
Net Debt - -
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
26-07-08 US$9.620 -2.34% 102,649
26-07-07 US$9.850 -1.79% 1,575,900
26-07-06 US$10.03 +2.03% 1,075,497
26-07-02 US$9.830 -0.51% 1,550,102
26-07-01 US$9.880 -4.08% 1,875,643
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.850USD
Average target price
20.29USD
Spread / Average Target
+105.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CADL Stock